Sort
16,300 grants matching “fatty liver disease”
Extracellular vesicle cargo and risk of NAFLD and NASH in Latino youth
$852,047Johanna K Distefano · Translational Genomics Research Inst · R01 · FY2022 · DK
Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments
$851,173Mark Scott Sundrud · Dartmouth-Hitchcock Clinic · R01 · FY2023 · AI
Lipidomics Biomarkers Link Sleep Restriction to Adiposity Phenotype, Diabetes, and Cardiovascular Risk
$850,665Bruce S Kristal · Brigham And Women'S Hospital · R01 · FY2021 · HL
A Multi-Center Group to Study Acute Liver Failure in Children
$850,189Robert H Squires · Children'S Hosp Pittsburgh/Upmc Hlth Sys · U01 · FY2007 · DK
Liver Cancer Disparities in Alaska Native and American Indian People
$850,177George Ioannou · University Of Washington · P20 · FY2022 · CA
Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments
$848,214Mark Scott Sundrud · Dartmouth-Hitchcock Clinic · R01 · FY2024 · AI
Xenobiotic Receptors
$848,152Frank J Gonzalez · Basic Sciences · Z01 · FY2007 · CA
Molecular Biology of the Metastatic Phenotype
$847,050Patricia Schriver Steeg · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA
Epigenetics of Development
$846,423Brant Weinstein · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2021 · HD
A school-based gardening obesity intervention for low-income minority children
$845,572Jaimie Nicole Davis · University Of Texas At Austin · R01 · FY2017 · HL
Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments
$845,443Mark Scott Sundrud · Dartmouth-Hitchcock Clinic · R01 · FY2025 · AI
Statistical methods and designs for correlated outcome and covariate errors in studies of HIV/AIDS
$845,194Bryan Earl Shepherd · Vanderbilt University Medical Center · R37 · FY2024 · AI
BASE:PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY&INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR
$843,496David Tweardy · University Of Tx Md Anderson Can Ctr · N01 · FY2020 · CA
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH
$842,388Suman Srinivasa · Massachusetts General Hospital · R01 · FY2023 · HL
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH
$842,357Suman Srinivasa · Massachusetts General Hospital · R01 · FY2022 · HL
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH
$840,829Suman Srinivasa · Massachusetts General Hospital · R01 · FY2024 · HL
Yale Mouse Metabolic Phenotyping Center
$840,442Gerald I Shulman · Yale University · U24 · FY2015 · DK
Yale Mouse Metabolic Phenotyping Center
$840,442Gerald I Shulman · Yale University · U24 · FY2014 · DK
Yale Mouse Metabolic Phenotyping Center
$840,442Gerald I Shulman · Yale University · U24 · FY2012 · DK
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH
$839,988Suman Srinivasa · Massachusetts General Hospital · R01 · FY2021 · HL
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
$839,731Inga Peter · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · HG
Discovery of Pharmacogenomic Biomarkers for Metformin Response
$837,363Kathleen M Giacomini · University Of California, San Francisco · R01 · FY2015 · GM
Pathophysiology of Metabolically Detrimental Changes in Adipose Distribution, Adipocyte Function, and Adipose Immune Environment on Antiretroviral Therapy
$836,628John Koethe · Vanderbilt University Medical Center · R01 · FY2023 · DK
Continuation of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASH
$836,133James A Tonascia · Johns Hopkins University · U01 · FY2010 · DK
A Multi-Center Group to Study Acute Liver Failure in Children
$834,478Robert H Squires · University Of Pittsburgh At Pittsburgh · U01 · FY2010 · DK